

Remarks on Substance of the interview

The Examiner telephoned and initiated a telephone interview with the undersigned on July 26, 2005. During the interview, the Examiner suggested that claims 3-4 be cancelled by an Examiner's Amendment and that the application would then be allowable. The undersigned agreed that claims 3-4 be cancelled by an Examiner's Amendment. The Applicants acknowledge that the Examiner's Amendment set forth on page 2 to 3 of the Notice of Allowance is acceptable to us.

Remarks on mistake regarding Powers of Attorneys


Applicants submitted PTO/SB/82 form of Revocation of Power of Attorney with New Power of Attorney and change of Correspondence Address, and PTO/SB/96 form of Statement under 37 CFR 3.73(b), in March 2005. Applicants noticed that these forms were received by USPTO on April 7, 2005. Accordingly, the Powers of Attorneys of Foley and Lardner LLP has been revoked and that Pfizer Inc, associated with custom number 28940, currently holds the Powers of Attorneys.

According to the Patent Application Information Retrieval page of the USPTO website, the Private Pair and the Notice of Allowance sent on August 3, 2005, this change of Powers of Attorneys has not been correctly entered by USPTO. Applicants respectfully request that USPTO corrects this mistake. Copies of the above mentioned forms and assignment papers submitted by Applicants in March are attached with this response.

If any fees other than those submitted herewith are due in connection with this response, please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: September 2, 2005



Ye Hua
Agent For Applicants
Registration No. 53,042

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-3020
Fax: (858) 678-8233